Chronic Idiopathic Constipation Market Share

ID: MRFR/Pharma/4475-HCR

100 Pages

Rahul Gotadki

October 2025

Chronic Idiopathic Constipation Market Research Report Information By Diagnosis (Blood Tests, Sigmoidoscopy, Colonoscopy, Balloon Expulsion Test, Anorectal Manometry), Treatment (Drugs), End-User (Hospitals & Clinics, Diagnostic Centers) -Forecast Till 2035

Chronic Idiopathic Constipation Market Infographic

Summary Table of Contents Segmentation Download PDF

Market Share

Chronic Idiopathic Constipation Market Share Analysis

Among the integral domains in gastrointestinal healthcare is Chronic Idiopathic Constipation (CIC) market, which is grappling with stiffer competition that has necessitated different market share positioning strategies by firms. Furthermore, businesses’ success and sustainability within this dynamic environment depend on effective strategies for success in CIC market. Investing in research and development to introduce innovative therapies and treatment options is an important way of moving forward with this strategy. By offering advanced medications and treatments, companies seek to differentiate themselves for better management of chronic idiopathic constipation conditions characterized by persistent, difficult-to-treat constipation without a known cause. This strategic approach meets the rising demand for accurate and efficient solutions facilitating such unique challenges as perennial constipation.

The pricing strategies play a role in determining the market share within Chronic idiopathic constipation market. Companies often use various pricing models like premium pricing for medication with added benefits as well as affordable options to increase patients’ accessibility. They price their products based on their perceived value that would cater for different markets such as hospital looking forward to state-of-the-art solutions or countries having different economic situations. For instance, through flexible pricing model they are able to be accessible throughout any given market thus broadening their reach.

Strategic collaborations and partnerships are key drivers in market share positioning for the CIC market. Collaborative projects involving these entities enhance knowledge sharing while at the same time putting diagnosis and treatment options into limelight. On one hand, these organizations exploit their partners’ strengths so as to gain competitive advantage in terms of research capabilities, marketing insights or distribution networks thus shoring up their overall presence.

Another important strategy used by companies is segmenting the customer base so that they can effectively target diverse groups within the Chronic Idiopathic Constipation (CIC) market. Medications tailored specifically towards meeting specific challenges faced by gastroenterologists, primary care physicians and patients suffering from CIC tend to have greater acceptability and usage by target markets. Different marketing mix strategies coupled with product portfolios are then developed to suit the unique requirements of these segments, thus enhancing their market position.

The positioning of companies’ market shares is significantly influenced by patient-centered approaches such as comprehensive support programs for patients and educational activities. Companies that offer assistance services, training resources and convenient communication measures targeting at satisfying patients or medical service providers are more likely to gain trust and loyalty from their stakeholders. This way, a company can have an increasing number of satisfied customers who would not only advocate for it but also recommend it to other potential customers thereby affecting its market share positively.

Market Highlights

Author

Rahul Gotadki

Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

FAQs

What is the expected growth rate of the global chronic idiopathic constipation market?

Chronic idiopathic constipation market is expected to expand at 7.16% CAGR from 2024-2032.

What is the major driver of the global chronic idiopathic constipation market?

Early detection of GI diseases at a preventive stage is the primary driver of the global chronic idiopathic constipation market.

What is the restraining factor of the global chronic idiopathic constipation market?

Low awareness of the treatment is the major factor expected to impede the global chronic idiopathic constipation market growth.

Which region can dominate in the global chronic idiopathic constipation market?

The Americas is expected to dominate the global chronic idiopathic constipation market till 2032 due to large number of cases of chronic constipation.

Who are the prominent players of the global chronic idiopathic constipation market?

Pfizer Inc, Salix Pharmaceuticals Ltd, Bayer, Sucampo Pharmaceuticals Inc, GlaxoSmithKline, Ironwood Pharmaceuticals, Chugai Pharmaceutical, Synergy Pharmaceuticals, Boehringer Ingelheim GmbH, Progenics Pharmaceuticals, F. Hoffmann-La Roche AG, Daewoong Co. Ltd., Actavis, Synergy Pharmaceuticals, Inc., Ferring International Center S., and Sanofi are prominent players of the global chronic idiopathic constipation market.

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

Market Summary

As per Market Research Future Analysis, the Chronic Idiopathic Constipation Market was valued at USD 4.57 Billion in 2023 and is projected to grow to USD 9.65 Billion by 2032, with a CAGR of 7.16% from 2024 to 2032. The market is driven by factors such as an aging population, increased accessibility to over-the-counter drugs, and a sedentary lifestyle. However, challenges include the availability of alternative treatments and reduced healthcare expenditure in developing countries. The COVID-19 pandemic has also influenced market dynamics, prompting changes in consumer behavior and healthcare practices. The North American region is the largest market, primarily due to a high prevalence of chronic constipation and significant healthcare investments.

Key Market Trends & Highlights

The Chronic Idiopathic Constipation Market is experiencing notable growth driven by various factors.

Market Size in 2023: USD 4.57 Billion Projected Market Size by 2032: USD 9.65 Billion CAGR from 2024 to 2032: 7.16% Major Growth Drivers: Aging population and increased OTC drug accessibility

Chronic Idiopathic Constipation Market

CAGR

7.16%

Market Size & Forecast

2023 Market Size	USD 4.57 Billion
2024 Projected Market Size	USD 5.21 Billion
2032 Projected Market Size	USD 9.65 Billion
CAGR (2024-2032)	7.16%

Major Players

Pfizer Inc (U.S.), Progenics Pharmaceuticals (U.S.), GlaxoSmithKline (U.K.), Sucampo Pharmaceuticals Inc (U.S.), Ironwood Pharmaceuticals (U.S.), Sanofi (France), Salix Pharmaceuticals Ltd (U.S.), Bayer (Germany)

Market Trends

The increasing prevalence of chronic idiopathic constipation, coupled with a growing awareness of gastrointestinal health, suggests a rising demand for innovative therapeutic options and patient-centered care strategies.

U.S. National Institute of Diabetes and Digestive and Kidney Diseases

Chronic Idiopathic Constipation Market Market Drivers

Aging Population

The aging population is a significant driver of the Global Chronic Idiopathic Constipation Market Industry. As individuals age, the incidence of chronic idiopathic constipation tends to increase due to various factors, including changes in diet, decreased physical activity, and the use of certain medications. With a growing elderly demographic globally, the demand for effective treatment options is likely to surge. This demographic shift is expected to contribute to the market's expansion, with estimates suggesting a market value of 5.21 USD Billion in 2024. Addressing the needs of this population is essential for healthcare providers and pharmaceutical companies alike.

Market Growth Projections

The Global Chronic Idiopathic Constipation Market Industry is poised for substantial growth, with projections indicating a market size of 5.21 USD Billion in 2024 and an anticipated increase to 11.9 USD Billion by 2035. This growth trajectory reflects a compound annual growth rate of 7.78% from 2025 to 2035. Factors contributing to this upward trend include the rising prevalence of chronic idiopathic constipation, advancements in treatment modalities, and increasing awareness among patients and healthcare providers. The market's expansion is indicative of the growing recognition of gastrointestinal health as a critical component of overall well-being.

Increasing Awareness and Education

The Global Chronic Idiopathic Constipation Market Industry is experiencing growth driven by heightened awareness and education regarding gastrointestinal health. Public health campaigns and educational initiatives have been instrumental in informing patients about the symptoms and treatment options available for chronic idiopathic constipation. This increased awareness is likely to lead to earlier diagnosis and treatment, thereby expanding the patient base. As a result, the market is anticipated to grow at a compound annual growth rate of 7.78% from 2025 to 2035. The emphasis on patient education is crucial in fostering proactive health management and improving overall quality of life.

Advancements in Treatment Modalities

Innovations in treatment modalities for chronic idiopathic constipation are pivotal to the expansion of the Global Chronic Idiopathic Constipation Market Industry. Recent advancements in pharmacological therapies, including new classes of medications and combination therapies, have shown promising efficacy in managing symptoms. For instance, the introduction of medications that target specific pathways in the gastrointestinal system has improved patient outcomes. This trend is likely to contribute to the market's growth, with projections indicating a rise to 11.9 USD Billion by 2035. The continuous development of novel therapeutic options is expected to enhance patient adherence and satisfaction, further stimulating market dynamics.

Regulatory Support and Approval Processes

Regulatory support and streamlined approval processes are crucial for the Global Chronic Idiopathic Constipation Market Industry. Governments and health authorities are increasingly recognizing the need for effective treatments for chronic idiopathic constipation, leading to expedited review processes for new therapies. This regulatory environment fosters innovation and encourages pharmaceutical companies to invest in research and development. As a result, the market is poised for growth, with projections indicating a potential market size of 11.9 USD Billion by 2035. The supportive regulatory landscape is likely to enhance the availability of novel treatment options for patients.

Rising Prevalence of Chronic Idiopathic Constipation

The Global Chronic Idiopathic Constipation Market Industry appears to be significantly influenced by the increasing prevalence of chronic idiopathic constipation among various demographics. Studies indicate that approximately 15% of the global population experiences this condition, with higher rates observed in older adults. This growing patient population necessitates effective treatment options, thereby driving market growth. As the industry evolves, it is projected that the market will reach 5.21 USD Billion in 2024, reflecting a robust demand for innovative therapies and management strategies. The rising awareness of gastrointestinal health further amplifies the need for solutions in this sector.

Market Segment Insights

Regional Insights

Key Companies in the Chronic Idiopathic Constipation Market market include

Industry Developments

Q1 2024: Ironwood Pharmaceuticals Announces FDA Approval of LINZESS® (linaclotide) for Pediatric Patients Aged 6-17 Years with Functional Constipation Ironwood Pharmaceuticals received FDA approval for an expanded indication of LINZESS® (linaclotide) to treat pediatric patients aged 6-17 years with functional constipation, marking a significant regulatory milestone in the chronic idiopathic constipation sector.
Q2 2024: Takeda and Ferring Pharmaceuticals Announce Strategic Partnership to Co-Develop Novel Constipation Therapies Takeda and Ferring Pharmaceuticals entered a strategic partnership to co-develop new therapies targeting chronic idiopathic constipation, aiming to accelerate innovation and expand treatment options in the market.
Q2 2024: Bausch Health Launches New Osmotic Laxative for Chronic Idiopathic Constipation in U.S. Market Bausch Health announced the commercial launch of a new osmotic laxative specifically indicated for chronic idiopathic constipation, expanding its gastrointestinal product portfolio in the United States.
Q2 2024: Renexxion Ireland Receives FDA Fast Track Designation for Naronapride in Chronic Idiopathic Constipation Renexxion Ireland was granted FDA Fast Track designation for its investigational drug Naronapride, intended for the treatment of chronic idiopathic constipation, facilitating expedited regulatory review.
Q3 2024: Ardelyx Announces Positive Phase 3 Results for Tenapanor in Chronic Idiopathic Constipation Ardelyx reported positive topline results from its Phase 3 clinical trial evaluating Tenapanor for chronic idiopathic constipation, supporting future regulatory submissions and potential market entry.
Q3 2024: Vanda Pharmaceuticals Appoints New Chief Medical Officer to Lead Gastrointestinal Drug Development Vanda Pharmaceuticals appointed a new Chief Medical Officer to oversee its gastrointestinal drug development programs, including candidates for chronic idiopathic constipation.
Q4 2024: Cosmo Pharmaceuticals Opens New Manufacturing Facility for Constipation Treatments in Italy Cosmo Pharmaceuticals inaugurated a new manufacturing facility in Italy dedicated to producing treatments for chronic idiopathic constipation, increasing its production capacity and supply chain resilience.
Q4 2024: RedHill Biopharma Secures $30 Million Series C Funding to Advance Chronic Idiopathic Constipation Pipeline RedHill Biopharma closed a $30 million Series C funding round to support the development and commercialization of its chronic idiopathic constipation drug candidates.
Q1 2025: Shionogi Receives EMA Approval for New CIC Drug in Europe Shionogi obtained European Medicines Agency (EMA) approval for its new chronic idiopathic constipation drug, enabling commercial launch across European markets.
Q1 2025: Salix Pharmaceuticals Announces U.S. Launch of New Extended-Release Constipation Therapy Salix Pharmaceuticals launched a new extended-release therapy for chronic idiopathic constipation in the United States, expanding its gastrointestinal product offerings.
Q2 2025: Progenity Inc. Signs Licensing Agreement with Major Pharma for CIC Diagnostic Platform Progenity Inc. entered a licensing agreement with a major pharmaceutical company to commercialize its diagnostic platform for chronic idiopathic constipation, aiming to improve patient management and outcomes.
Q2 2025: Theravance Biopharma Announces Positive Results from Phase 2 Study of New CIC Treatment Theravance Biopharma announced positive results from a Phase 2 clinical study of its investigational treatment for chronic idiopathic constipation, supporting further development and potential regulatory filings.

While not a direct diagnostic tool for CIC itself, a significant development in the broader diagnostic approach for chronic bowel symptoms (including constipation) is the strong recommendation by major gastroenterology bodies (like the American College of Gastroenterology - ACG and British Society of Gastroenterology - BSG) to use non-invasive markers like C-reactive protein (CRP) and fecal calprotectin. These blood and stool tests help to effectively rule out inflammatory bowel disease (IBD) in patients with suspected Irritable Bowel Syndrome with Constipation (IBS-C) or unexplained chronic constipation, especially when alarm features are absent.

This reduces the reliance on more invasive diagnostic procedures like colonoscopy unless specific alarm signs are present.

Future Outlook

Chronic Idiopathic Constipation Market Future Outlook

The Chronic Idiopathic Constipation Market is projected to grow at a 7.78% CAGR from 2024 to 2035, driven by increasing prevalence and innovative treatment options.

New opportunities lie in:

Developing personalized therapies targeting specific patient demographics. Investing in <a href="https://www.marketresearchfuture.com/reports/digital-healthcare-market-7636">digital health</a> solutions for remote patient monitoring. Expanding distribution channels to enhance product accessibility in emerging markets.

By 2035, the market is expected to achieve substantial growth, reflecting evolving consumer needs and advancements in treatment.

Market Segmentation

Report Overview

Chronic Idiopathic Constipation Market Segmentation

Chronic Idiopathic Constipation Market Industry Developments
{"Q1 2024: Ironwood Pharmaceuticals Announces FDA Approval of LINZESS® (linaclotide) for Pediatric Patients Aged 6-17 Years with Functional Constipation"=>[]}
{"Q2 2024: Takeda and Ferring Pharmaceuticals Announce Strategic Partnership to Co-Develop Novel Constipation Therapies"=>[]}
{"Q2 2024: Bausch Health Launches New Osmotic Laxative for Chronic Idiopathic Constipation in U.S. Market"=>[]}
{"Q2 2024: Renexxion Ireland Receives FDA Fast Track Designation for Naronapride in Chronic Idiopathic Constipation"=>[]}
{"Q3 2024: Ardelyx Announces Positive Phase 3 Results for Tenapanor in Chronic Idiopathic Constipation"=>[]}
{"Q3 2024: Vanda Pharmaceuticals Appoints New Chief Medical Officer to Lead Gastrointestinal Drug Development"=>[]}
{"Q4 2024: Cosmo Pharmaceuticals Opens New Manufacturing Facility for Constipation Treatments in Italy"=>[]}
{"Q4 2024: RedHill Biopharma Secures $30 Million Series C Funding to Advance Chronic Idiopathic Constipation Pipeline"=>[]}
{"Q1 2025: Shionogi Receives EMA Approval for New CIC Drug in Europe"=>[]}
{"Q1 2025: Salix Pharmaceuticals Announces U.S. Launch of New Extended-Release Constipation Therapy"=>[]}
{"Q2 2025: Progenity Inc. Signs Licensing Agreement with Major Pharma for CIC Diagnostic Platform"=>[]}
{"Q2 2025: Theravance Biopharma Announces Positive Results from Phase 2 Study of New CIC Treatment"=>[]}

Report Scope

Report Attribute/Metric	Details
Market Size 2023	4.57 (USD Billion)
Market Size 2024	5.21 (USD Billion)
Market Size 2032	9.65 (USD Billion)
Compound Annual Growth Rate (CAGR)	7.16 % (2024 - 2032)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year	2023
Market Forecast Period	2024 - 2032
Historical Data	2019 - 2023
Geographies Covered	North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Key Vendors	Actavis (U.S.), Chugai Pharmaceutical (Japan), Ferring International Center S.A.(Switzerland), Synergy Pharmaceuticals (U.S.), Pfizer Inc (U.S.), GlaxoSmithKline (U.K.), Sanofi (France), Bayer (Germany), Salix Pharmaceuticals Ltd (U.S.), Sucampo Pharmaceuticals Inc (U.S.), Ironwood Pharmaceuticals (U.S.), Progenics Pharmaceuticals (U.S.), F. Hoffmann-La Roche AG (Switzerland), Boehringer Ingelheim GmbH (Germany), Daewoong Co. Ltd.(South Korea), Synergy Pharmaceuticals, Inc. (U.S.) and others
Key Market Opportunities	New product launches and R&D Amongst major key Players
Key Market Drivers	· Increasing number of patients having GI diseases · Disorders due to change in dietary pattern

Market Highlights

Author

Rahul Gotadki

Assistant Manager

She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Latest Comments

John Doe

john@example.com

This is a great article! Really helped me understand the topic better.

Posted on July 23, 2025, 10:15 AM

Jane Smith

jane@domain.com

Thanks for sharing this. I’ve bookmarked it for later reference.

Posted on July 22, 2025, 7:45 PM

View All